Cargando…

PRKAR2B plays an oncogenic role in the castration-resistant prostate cancer

Castration-resistant prostate cancer (CRPC) is an advanced form of prostate cancer. Despite some progresses have been made, the mechanism of CRPC development is still largely unknown, including the genes involved in its development have not been well defined. Here, we identifiedPRKAR2B to be a gene...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sha, Jianjun, Xue, Wei, Dong, Baijun, Pan, Jiahua, WU, Xiaorong, Li, Dong, Liu, Dongming, Huang, Yiran
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351617/ https://www.ncbi.nlm.nih.gov/pubmed/28008150 http://dx.doi.org/10.18632/oncotarget.14044

Ejemplares similares

PRKAR2B‐HIF‐1α loop promotes aerobic glycolysis and tumour growth in prostate cancer
por: Xia, Lei, et al.
Publicado: (2020)

Abiraterone acetate for chemotherapy-naive metastatic castration-resistant prostate cancer: a single-centre prospective study of efficacy, safety, and prognostic factors
por: Fan, Liancheng, et al.
Publicado: (2018)

TIKI2 is upregulated and plays an oncogenic role in renal cell carcinoma
por: Yuan, Xiaodong, et al.
Publicado: (2016)

AB140. Efficacy of radical prostatectomy combined with neoadjuvant chemotherapy in the treatment of locally advanced prostate cancer: preliminary experiences from a single center
por: Xue, Wei, et al.
Publicado: (2016)

Efficacy of neoadjuvant docetaxel + cisplatin chemo-hormonal therapy versus docetaxel chemo-hormonal therapy in patients with locally advanced prostate cancer with germline DNA damage repair gene alterations
por: Chi, Chenfei, et al.
Publicado: (2022)

Combination of the NRF2 Inhibitor and Autophagy Inhibitor Significantly Inhibited Tumorigenicity of Castration-Resistant Prostate Cancer
por: Zhang, Yong, et al.
Publicado: (2022)

Platelet to lymphocyte ratio as an independent prognostic indicator for prostate cancer patients receiving androgen deprivation therapy
por: Wang, Yanqing, et al.
Publicado: (2016)

Ductal adenocarcinoma of the prostate: immunohistochemical findings and clinical significance
por: Sha, Jianjun, et al.
Publicado: (2013)

Decreased TSPAN1 promotes prostate cancer progression and is a marker for early biochemical recurrence after radical prostatectomy
por: Xu, Fan, et al.
Publicado: (2016)

Serum Pre-Albumin Predicts the Clinical Outcome in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Abiraterone
por: Fan, Liancheng, et al.
Publicado: (2017)

Incidental Prostate Cancer at the Time of Cystectomy: The Incidence and Clinicopathological Features in Chinese Patients
por: Pan, Jiahua, et al.
Publicado: (2014)

CXCL1-LCN2 paracrine axis promotes progression of prostate cancer via the Src activation and epithelial-mesenchymal transition
por: Lu, Yongning, et al.
Publicado: (2019)

PRKAR1A and Thyroid Tumors
por: Pitsava, Georgia, et al.
Publicado: (2021)

Circ_0000811 acts as a miR-15b sponge and inhibits Prkar2a-mediated JAK2/STAT1 pathway to attenuate cerebral ischemic vertigo
por: Huang, Rui, et al.
Publicado: (2022)

m(6)A-induced repression of SIAH1 facilitates alternative splicing of androgen receptor variant 7 by regulating CPSF1
por: Xia, Lei, et al.
Publicado: (2022)

Engineering the MoS(2)/MXene Heterostructure for Precise and Noninvasive Diagnosis of Prostate Cancer with Clinical Specimens
por: Xie, Shaowei, et al.
Publicado: (2023)

Metastatic Castration-Resistant Prostate Cancer Remains Dependent on Oncogenic Drivers Found in Primary Tumors
por: Einstein, David J., et al.
Publicado: (2021)

Extended lymphadenectomy for high-risk prostate cancer in patients with chronic lymphocytic leukemia may not be necessary: a report of two cases
por: Zhu, Yinjie, et al.
Publicado: (2019)

Novel Mutation in PRKAR1A in Carney Complex
por: Park, Ko Un, et al.
Publicado: (2012)

Hematopoietic neoplasms in Prkar2a-deficient mice
por: Saloustros, Emmanouil, et al.
Publicado: (2015)

Albumin and Fibrinogen Combined Prognostic Grade Predicts Prognosis of Patients with Prostate Cancer
por: Wang, Yanqing, et al.
Publicado: (2017)

LncRNA MALAT1 enhances oncogenic activities of EZH2 in castration-resistant prostate cancer
por: Wang, Dejie, et al.
Publicado: (2015)

Constitutively Active AR-V7 Plays an Essential Role in the Development and Progression of Castration-Resistant Prostate Cancer
por: Qu, Yuanyuan, et al.
Publicado: (2015)

Risk factors for progression to castration-resistant prostate cancer in metastatic prostate cancer patients
por: Lin, Ting-Ting, et al.
Publicado: (2019)

Surface-enhanced Raman spectroscopy of serum accurately detects prostate cancer in patients with prostate-specific antigen levels of 4–10 ng/mL
por: Chen, Na, et al.
Publicado: (2017)

Molecular and cellular mechanisms of castration resistant prostate cancer
por: Huang, Yiqiao, et al.
Publicado: (2018)

Histone methyltransferase PRMT6 plays an oncogenic role of in prostate cancer
por: Almeida-Rios, Diogo, et al.
Publicado: (2016)

The Diagnostic Value of PI-RADS v2.1 in Patients with a History of Transurethral Resection of the Prostate (TURP)
por: Liu, Jiazhou, et al.
Publicado: (2022)

Crosstalk between KIF15 and AR in castrate-resistant prostate cancers
por: Yang, Hanny, et al.
Publicado: (2022)

Nonmetastatic Castration-Resistant Prostate Cancer
por: Hong, Jun Hyuk, et al.
Publicado: (2014)

Darolutamide For Castration-Resistant Prostate Cancer
por: Bastos, Diogo A, et al.
Publicado: (2019)

The role of glutamine metabolism in castration-resistant prostate cancer
por: Zhao, Bing, et al.
Publicado: (2023)

Impact of Time to Castration Resistance on Cytoreductive Radiotherapy in Metastatic Castration-Resistant Prostate Cancer
por: Mai, Lixin, et al.
Publicado: (2020)

Dynamic changes in gene alterations during chemotherapy in metastatic castrate resistant prostate cancer
por: Tan, Winston, et al.
Publicado: (2022)

Docetaxel remodels prostate cancer immune microenvironment and enhances checkpoint inhibitor-based immunotherapy
por: Ma, Zehua, et al.
Publicado: (2022)

Curcumin Nanoparticles and Their Cytotoxicity in Docetaxel-Resistant Castration-Resistant Prostate Cancer Cells
por: Tanaudommongkon, Irin, et al.
Publicado: (2020)

Aurora Kinase A-YBX1 Synergy Fuels Aggressive Oncogenic Phenotypes and Chemoresistance in Castration-Resistant Prostate Cancer
por: Nikhil, Kumar, et al.
Publicado: (2020)

Recurrent somatic mutations of PRKAR1A in isolated cardiac myxoma
por: He, Jian, et al.
Publicado: (2017)

PRKAR1A deficiency impedes hypertrophy and reduces heart size
por: Liu, Yuening, et al.
Publicado: (2020)

STK25 inhibits PKA signaling by phosphorylating PRKAR1A
por: Zhang, Xiaokan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_etgqbmeh7bhtm8uf0gqm66cdbj